Pearl Steinzor

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

Despite the availability of several noninvasive tests for colorectal cancer, prioritizing blood-based tests may result in higher costs and worse population-level outcomes.

The FDA cites cancer risk and the Delaney Clause in its decision to revoke food and drug uses of the dye.

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality of life for patients with psoriasis.

There is limited awareness and utilization of supplemental benefits among Medicare Advantage beneficiaries, with cost-sharing and out-of-pocket spending playing key roles, a new study has found.

New research examines how ethnicity impacts colorectal cancer diagnosis, early-onset colorectal cancer (CRC) prevalence, and stage at diagnosis.

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Psychological resilience plays an important role in managing psoriasis symptoms and enhancing patient well-being, study reveals.

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in patients with hormone receptor–positive breast cancer.

Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in patients with resected colorectal cancer (CRC).

Trend tracking and harm reduction policies may help alleviate the high rate of overdose deaths in the US, according to one study.

Record numbers have enrolled in Affordable Care Act (ACA) coverage as open enrollment continues through January 15, 2025.

Study highlights barriers to care, treatment preferences, and interest in research participation in psoriasis in the Latine community.

Self-efficacy–based sexual counseling may improve sexual function among breast cancer survivors, study finds.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, continues his discussion on treatment approaches for patients with cardiovascular-kidney-metabolic (CKM) syndrome.

How does age, sex, comorbidity, and screening history influence the cost-effectiveness of continuing colorectal cancer (CRC) screening in older adults?

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.

The European Society for Medical Oncology (ESMO) Congress featured findings on overall survival, disparities, and artificial intelligence in cancer research.

The most-read psoriasis content in 2024 covered efficacy and safety findings of various drug clinical trials.

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the interconnected condition of cardiovascular-kidney-metabolic (CKM) syndrome, which includes obesity, diabetes, chronic kidney disease, and cardiovascular disease.

Understanding postural orthostatic tachycardia syndrome is important in order to improve prevention and outcomes.

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).